Martin Dunbar

Alkermes (United States) — United States

Medicine · Health Sciences

37h-index8.0kcitations99works2.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(28), Acute Myeloid Leukemia Research(15), Chronic Myeloid Leukemia Treatments(14), PARP inhibition in cancer therapy(14), Lymphoma Diagnosis and Treatment(13)

Publications95 total

Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial
Neuropsychiatric Disease and Treatment·2025Open Access
Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia
Neuropsychiatric Disease and Treatment·2025· 3 citedOpen Access
Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan
The Journal of Clinical Psychiatry·2024· 6 citedOpen Access
Getting to Grippe With Influenza: An Investigation of Why the Disease Is Called That
University of Southern Denmark Research Portal (University of Southern Denmark)·2024Open Access
O10-2 Telisotuzumab vedotin monotherapy in Asian patients with c-Met–overexpressing advanced non-small cell lung cancer
Annals of Oncology·2023Open Access
O7-4 Phase 1b efficacy of telisotuzumab vedotin and osimertinib in Asian vs non-Asian patients with advanced NSCLC
Annals of Oncology·2023· 1 citedOpen Access
Data from Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
2023Open Access
Supplementary Figures S1 - S3, Table S1 from Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
2023Open Access
Supplementary Figures S1 - S3, Table S1 from Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
2023Open Access
Data from Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
2023Open Access
Supplementary Data from Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
2023Open Access
Data from Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
2023Open Access
Supplementary Data from Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
2023Open Access
Data from Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
2023Open Access
Considering Precision and Utility When we Talk About Pain. Comment on Cohen et al
Journal of Pain·2022· 14 citedOpen Access
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer
Journal of Clinical Oncology·2022· 97 citedOpen Access
A systematic review of economic analyses of psychological interventions and therapies in health-related settings
BMC Health Services Research·2022· 7 citedOpen Access
Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2022· 70 cited
Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, <i>EGFR</i>-mutated non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology·2022· 20 cited
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
Investigational New Drugs·2022· 27 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Rod Humerickhouse(14), Ahmed Hamed Salem(12), Ming Zhu(11), Suresh Agarwal(11), Lori A. Gressick(8), Sari H. Enschede(8), Andrew W. Roberts(7), Matthew S. Davids(7), John M. Pagel(7), Brad S. Kahl(7), John F. Gerecitano(7), Mary Ann Anderson(7), Shekman Wong(7), William G. Wierda(7), John F. Seymour(6), Mack Mabry(6), Thomas J. Kipps(5), Elisa Cerri(5), Marina Konopleva(5), Daniel A. Pollyea(5)